VIDEO: Pipeline drugs predicted to have significant impact on dry eye disease
Click Here to Manage Email Alerts
NEW ORLEANS — New research in dry eye disease suggests the next few years will bring significant advancements in treatment for patients, according to a speaker at Academy ’23.
“We’re starting to see a lot of drugs in the pipeline that are going to be really useful for us as dry eye practitioners,” Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA, director of the Centre for Ocular Research & Education at the University of Waterloo, told Healio.
Jones and colleagues recently studied AZR-MD-001 (Azura Ophthalmics), an investigational selenium sulfide ointment for adults with meibomian gland dysfunction.
“Within as short a time period as 2 weeks, we were able to see a significant improvement in the quality and the amount of meibum that was released,” Jones said. “And over a 6-month time frame, the difference between the drug vs. the vehicle was significant.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts